glp-1 drugs for type 2 diabetes Popular Drug May Reduce Glaucoma Risk How GLP-1 medications are transforming
Description
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study
Preliminary research indicates that the activation of GLP-1R facilitates mechanisms essential for telomere stability, potentially delaying cellular aging and extending cellular lifespan
In a model of Type 1 diabetic nephropathy, Kawasaki et al explored the antifibrotic properties of linagliptin and discovered that, after 4 weeks, it decreased diabetic kidney fibrosis, which was associated with the repair of microRNA29s and the suppression of EndMT
Data availability No datasets were generated or analyzed during the current study
In addition, in recent years, a significant role has been attributed to coronary microvascular dysfunction as one of the pathogenetic factors for HFpEF progression
Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans
